MeiraGTx Receives FDA RMAT Designation for Innovative Parkinson’s Disease Gene Therapy
MeiraGTx Holdings plc has received FDA RMAT designation for its Parkinson’s disease treatment, AAV-GAD, a gene therapy that could bring new hope to patients with the complex neurological disorder.
2 minutes to read